Goodwin Procter advised Envisagenics, Inc. on the deal. Envisagenics, Inc. announced a research collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The multi-year collaboration will leverage...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Landmark Bio™ on the deal. Landmark Bio™ announced the opening of its state-of-the-art full-spectrum development and biomanufacturing facility in Watertown, Massachusetts. The 44,000 square-foot...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Envisagenics on the deal. Envisagenics announced its collaboration with Biogen Inc. (Nasdaq: BIIB) to advance ribonucleic acid (RNA) splicing research within central nervous...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP and Advokatfirman Delphi advised Olink Holding AB on the deal, while Baker McKenzie legal advisor to minority selling shareholders. Sweden-based Olink Holding AB...
You must be a Standard 1 Year member to access this content.
